HALOZYME THERAPEUTICS, INC.(HALO)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
HALOZYME THERAPEUTICS, INC. (HALO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HALO at 77.2/100 on a 32-signal composite quality model, placing it at rank #72 of 2,960 stocks — the top 5% of the AI-ranked universe. HALO scores in the top quartile across balance sheet strength (95.0), free cash flow (94.4), revenue growth (91.0). Areas of concern include institutional flow (30.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HALOZYME THERAPEUTICS, INC. reports quarterly revenue of $481.0M, net income of $229.9M, free cash flow of $236.7M. Top institutional holders of HALO by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. HALO trades on the Nasdaq exchange and files with the SEC under CIK 1159036. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HALO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HALOZYME THERAPEUTICS, INC. directly from SEC EDGAR.
AI Quality Score
77.2/100
AI Rank
#72
Revenue
$481.0M
Net Income
$229.9M
Free Cash Flow
$236.7M
HALO key financials by period
HALOZYME THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.4B
$316.9M
33.6%
FY 2024
10-K
$1.0B
$444.1M
54.3%
FY 2023
10-K
$829.3M
$281.6M
40.7%
FY 2022
10-K
$660.1M
$202.1M
40.5%
FY 2021
10-K
$443.3M
$402.7M
62.2%
FY 2020
10-K
$267.6M
$129.1M
53.9%
Institutions holding HALO
Institutional investors reporting a position in HALOZYME THERAPEUTICS, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenue rose to $481.0M from $325.7M as royalties grew 50% to $307.7M on DARZALEX SC and VYVGART Hytrulo uptake, with net income of $229.9M.
Biggest Revenue Drivers
Royalties$307.7M+50% YoY
Continued sales uptake of ENHANZE partner products launched since 2020, partially diluted by price erosion on Herceptin and MabThera
Product sales, net$129.6M+59% YoY
Increased bulk rHuPH20 sales driven by partner demand, plus XYOSTED contributions from continued market growth
Biggest Revenue Drivers
Total revenue: $481.0M
Royalties$307.7M+50% YoY
Continued sales uptake of ENHANZE partner products launched since 2020, partially diluted by price erosion on Herceptin and MabThera
Within Royalties
DARZALEX$152.2M+27% YoY
VYVGART Hytrulo$72.6M+143% YoY
Product sales, net$129.6M+59% YoY
Increased bulk rHuPH20 sales driven by partner demand, plus XYOSTED contributions from continued market growth
Revenues under collaborative agreements$43.7M+13% YoY
Primarily due to the timing of milestones achieved; included $35.5M of upfront license and target nomination fees
Largest Expense Items
Cost of sales$79.2M+71% YoY
Primarily due to an increase in bulk rHuPH20 sales
Selling, general and administrative$57.0M+37% YoY
Consulting and professional fees including patent infringement litigation costs, the Elektrofi and Surf Bio acquisitions, and higher compensation expense
Amortization of intangibles$29.5M+66% YoY
Due to the acquisition of Elektrofi in November 2025
Research and development$27.7M+58% YoY
Primarily due to the acquisition of Elektrofi and Surf Bio in the fourth quarter of 2025
Margins: The filing gives no explicit gross or operating margin discussion; it attributes the 71% cost of sales increase to higher bulk rHuPH20 sales, against total operating expenses of $193.3M and operating income of $287.7M.
Watch Items from the Filing
A partner may return a Hypercon target by February 2027; if so, the $450.6M customer relationship intangible and goodwill could face a material interim impairment charge.
Collaboration revenue is lumpy: sales-based milestones fell to zero from $10.0M and event-based milestones to $5.7M from $24.5M year over year.
Total convertible note principal of $2.18B, with $209.6M of 2027 Notes now classified as current portion of long-term debt against $231.0M of cash and marketable securities.
New May 2026 program to repurchase up to $1.0B of stock by December 31, 2028; 4.8M shares repurchased for $332.7M at $69.30 average in Q2.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
